A-Phase: tirofiban; Z-Phase simvastatin

Phase 3Small molecule

A-Phase: tirofiban; Z-Phase simvastatin is one of 22 small molecule programs targeting Chest pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chest PainActive, not recruiting

Chest PainPhase 3

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Chest Pain

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

1 2

Voltaren

Novartis

Approved

1 3

Marinol

Alnylam Pharmaceuticals

Approved

1 4

Celexa

AbbVie

Approved

1 5

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

2 6

Zocor

OOrganon and Co

Approved

1 7

Neurontin

VViatris Specialty LLC

Approved

1 8

Zoloft

VViatris Specialty LLC

Approved

1 9

Pepcid

Tofranil

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chest pain1 trial

Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)

Completed·OOrganon and Co·Phase 3·NCT00251576·4,497 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for A-Phase: tirofiban; Z-Phase simvastatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — A-Phase: tirofiban; Z-Phase simvastatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for A-Phase: tirofiban; Z-Phase simvastatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Organon and Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOrganon and Co

A-Phase: tirofiban; Z-Phase simvastatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chest pain1 trial

References

Drug Info

Quick Facts

Related News